ORYZON to present at the 3rd Neuroscience Innovation Forum in San Francisco
MADRID, SPAIN and CAMBRIDGE MA.
- CEO and CMO to present recent progress of vafidemstat
- Will also participate in 9th Annual LifeSci Advisors Corporate Access Event 2020
- Both events during week of the JP Morgan Healthcare Conference
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that its management will present recent progress of vafidemstat in central nervous system (CNS) indications at the 3rd Neuroscience Innovation Forum in San Francisco on January 12.